Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02088073
Other study ID # ZS-004
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 31, 2014
Est. completion date January 31, 2015

Study information

Verified date November 2018
Source ZS Pharma, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among hyperkalemic subjects in whom normokalemia was established during the open-label acute phase versus no difference between each ZS dose (highest to lowest) versus placebo control (null hypothesis).


Description:

Approximately 275 subjects with hyperkalemia (two consecutive i-STAT potassium levels ≥ 5.1 mmol/l, taken 60 minutes apart at baseline) will be enrolled in the Open-label Acute Phase to provide 232 subjects in the Double Blind Randomized Maintenance Phase.

Initially all subjects will receive open-label ZS at a dose of 10g three times a day (tid) for 48 hours (AP). Subjects who achieve normokalemia (i-STAT potassium values between 3.5 to 5.0 mmol/l, inclusive) on the morning of Study Day 3 (after 6 doses of 10g ZS) will then, in a double-blind fashion, be randomized 4:4:4:7 to receive one of three doses of ZS (5g, 10g or 15g) or placebo control, qd for the following 28 days (DBRMP).

Safety and tolerability will be assessed on an ongoing basis by an Independent Data Monitoring Committee (iDMC). Each active dose group in the DBRMP will consist of 49 subjects and the placebo control group will consist of 85 subjects for a total of 232 subjects to detect a 0.6 effect size difference between each ZS dose (from highest to lowest) and placebo control; the 4:4:4:7 allocation optimizes the multiple comparisons to the placebo control for the DBRMP.


Recruitment information / eligibility

Status Completed
Enrollment 258
Est. completion date January 31, 2015
Est. primary completion date August 31, 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Provision of written informed consent.

- Over 18 years of age.

- Two consecutive i-STAT potassium values, measured 60-minutes apart, both =5.1 mmol/l and measured within 1 day of the first ZS dose on AP Study Day 1.

- Ability to have repeated blood draws or effective venous catheterization.

- Women of childbearing potential must be using two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at AP Study Day 1. Women who are surgically sterile or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential.

Exclusion Criteria:

- Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed blood specimen, history of severe leukocytosis or thrombocytosis.

- Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for hyperammonemia within 7 days prior to the first dose of study drug.

- Subjects treated with resins (such as sevelamer acetate or sodium polystyrene sulfonate [SPS; e.g. Kayexalate®]), calcium acetate, calcium carbonate, or lanthanum carbonate, within 7 days prior to the first dose of study drug.

- Subjects with a life expectancy of less than 3 months.

- Subjects who are severely physically or mentally incapacitated and who in the opinion of investigator are unable to perform the subjects' tasks associated with the protocol.

- Women who are pregnant, lactating, or planning to become pregnant.

- Subjects with diabetic ketoacidosis.

- Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.

- Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.

- Randomization into the previous ZS-002 or ZS-003 studies.

- Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.

- Subjects with cardiac arrhythmias that require immediate treatment.

- Subjects on dialysis.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sodium zirconium cyclosilicate
Sodium zirconium cyclosilicate
Placebo
Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
ZS Pharma, Inc.

Countries where clinical trial is conducted

United States,  Australia,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Serum Potassium Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT Population). The least squares means (LSMeans) are dervied from a mixed effects model of serial log transformed S-K values between Days 8 and 29 with patients as a random effect and the following fixed effects terms: MP treatment group; AP baseline eGFR; AP and MP baseline S-K levels, age categories (<55, 55-64, >= 65 years); and binary indicators for RAAS inhibitors use, CKD, CHF, and DM. The LSmeans estimate obtained from the above model is back-transformed and presented as the lsmeans of all available S-K values during the Maintenance phase study Days 8 to 29. 22 Days; Maintenance Phase Days 8 - 29, inclusive.
Secondary The Number of Normokalemic Days Between Maintenance Phase Study Days 8 to 29, Inclusive (MP-ITT). The number of normokalemic days during the Maintenance Phase Study Days 8 to 29 is calculated assuming that the interval between assessments is normokalemic only if both the beginning and end assessments for that time interval display normal S-K values (i.e. 3.5 - 5.0 mmol/L) 22 days; Maintenance Phase Day 8 - 29, inclusive.
Secondary Mean Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit . Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.
Secondary Mean Percent Change in S-K Levels From Acute Phase Baseline to Maintenance Phase Study Day 2 to Day 29/Exit, Inclusive . Acute Phase baseline to Maintenance Phase Study Day 2 to Day 29/Exit, inclusive.
Secondary Mean Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit. Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.
Secondary Mean Percent Change in S-K Levels From Maintenance Phase Baseline to Maintenance Phase Day 2 to Day 29/Exit. Maintenance phase baseline to Maintenance Phase Study Day 29/Exit, inclusive.
Secondary Median Time to Hyperkalemia (S-K = 5.1mmol/L) Maintenance Phase baseline to maintenance Phase Study Day 29/Exit.
Secondary Mean S-K Intra-subject Standard Deviation Calculated Among Subjects With = 2 Values on or After Maintenance Phase Study Day 8 22 days; Maintenance Phase Day 8 - 29
Secondary Proportion of Subjects Who Remained Normokalemic During Maintenance Phase Maintenance Phase Study Days 1, 2, 5, 8, 12, 15, 19, 22, 26, 29, and 35, inclusive.
Secondary Median Time to Relapse in S-K Values Median time to relapse in S-K values (return to original Acute Phase S-K baseline value) Maintenance phase Study Day 1 to Study Day 29/Exit.
Secondary Exponential Rate of Change in S-K Values During the Acute Phase at 24 Hours and 48 Hours of Study Drug Treatment. Acute Phase 24 hours and Acute Phase 48 hours.
Secondary Mean Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase. All measured time intervals post dose during the Acute Phase.
Secondary Mean Percent Change From Baseline in S-K Values (Blood) at All Measured Time Intervals Post Dose Acute Phase. All measured time intervals post dose during the Acute Phase.
Secondary Proportion of Subjects Who Achieve Normokalemia During the Acute Phase at 24 and 48 Hours After Start of Dosing Through 48 hours acute phase
Secondary Median Time to Normalization (3.50-5.0 mmol/L) in S-K Levels in the 48 Hours of Initial Treatment Through 48 hours acute phase
See also
  Status Clinical Trial Phase
Completed NCT03172702 - Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia Phase 3
Terminated NCT05056727 - A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Phase 3
Recruiting NCT05766839 - Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age Phase 2
Completed NCT02609841 - POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study N/A
Recruiting NCT06277128 - A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia. Phase 2
Recruiting NCT04789239 - OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure Phase 2
Completed NCT05029310 - Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients Phase 4
Terminated NCT04443608 - Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management Phase 4
Completed NCT02607085 - REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study N/A
Completed NCT03283267 - A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS) Phase 1
Recruiting NCT06036823 - 5 Versus 10 Units of Insulin in Hyperkalemia Management Phase 4
Recruiting NCT05173584 - Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects. Phase 4
Completed NCT05184998 - Description of the Clinical Outcomes of Hospitalized Patients With Heart Failure With Different Serum Potassium Levels
Completed NCT01737697 - Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia Phase 3
Completed NCT01493024 - Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia Phase 2
Completed NCT04207203 - Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study N/A
Completed NCT05382988 - Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy Phase 3
Completed NCT04217590 - Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects Phase 3
Recruiting NCT03096561 - Measurement of Serum Potassium Rate During Accidental Hypothermia. N/A
Completed NCT03326583 - The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia Phase 2